Mechanisms of Vasovagal Syncope

Status Active, not recruiting

Clinical Trial Summary

Vasovagal Syncope (simple postural faint) is the most common cause of acute loss of consciousness. Postural tachycardia syndrome(POTS) is the most common chronic form of postural lightheadedness. Together they afflict many Americans, mostly young women, who are prevented from gainful employ or school attendance. The underlying mechanism is not known. Our past work suggests that a simple molecule, nitric oxide, acts to subvert normal blood flow controls causing blood to pool in the gut when standing. Our proposal will show the mechanism behind this problem and will indicate effective medical treatments. Patients will be compared to healthy control subjects.

Clinical Trial Description

Vasovagal Syncope (VVS,simple faint) is the most common cause of transient loss of consciousness and is the acute episodic form of orthostatic intolerance(OI). Postural tachycardia syndrome (POTS) is the common chronic form of OI. Both are defined by debilitating symptoms and signs while upright relieved by recumbency. Pathophysiological mechanisms have remained elusive although our past work shows that excessive upright central hypovolemia results from splanchnic pooling due to defective splanchnic arterial and venous constriction. Preliminary data support the hypothesis that production of nitric oxide (NO) is enhanced in these patients resulting in reduced sympathetic noradrenergic neurotransmission at pre-junctional and post-junctional sites. Our approach is two-fold: 1) We will use intradermal microdialysis and laser Doppler flowmetry (LDF) to delineate the microvascular mechanisms of NO modulation of noradrenergic neurotransmission free of confounding systemic reflex changes. 2) We will systemically apply this mechanism to a model of orthostatic stress, lower body negative pressure(LBNP), while measuring cardiac output by inert gas rebreathing, regional blood volume, and regional blood flow using plethysmographic techniques focusing on splanchnic changes, and muscle sympathetic nerve activity by peroneal microneurography. We will study synaptic peripheral neurotransmission of Norepinephrine and how it is affected by supplemental NO and by nitric oxide synthase inhibitor. ;

Study Design

Related Conditions & MeSH terms

Postural Orthostatic Tachycardia Syndrome
Postural Tachycardia Syndrome
Syncope
Syncope, Vasovagal
Tachycardia
Vasovagal Syncope

Clinical Trial Details

NCT number	NCT01791816
Study type	Interventional
Source	New York Medical College
Contact
Status	Active, not recruiting
Phase	Early Phase 1
Start date	February 2013
Completion date	December 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03124355` - Vagal Stimulation in POTS	Phase 1
Recruiting	`NCT04310644` - Autonomic Small Fiber Neuropathy and Ehlers Danlos Syndromes - Prospective Study and Registry
Completed	`NCT03253120` - Alterations of Attention in POTS Depending on Body Position and Hydration	N/A
Completed	`NCT03919773` - IVIG (Gamunex-C) Treatment Study for POTS Subjects	Phase 1/Phase 2
Active, not recruiting	`NCT01988883` - Modafinil and Cognitive Function in POTS	Early Phase 1
Active, not recruiting	`NCT01000350` - Intravenous (IV) Saline and Exercise in Postural Tachycardia Syndrome (POTS)	N/A
Recruiting	`NCT00409435` - A Study of Pyridostigmine in Postural Tachycardia Syndrome	Phase 2
Completed	`NCT00770484` - Effect of Exercise in OI	N/A
Completed	`NCT00581022` - Objective Sleep Disturbances in Orthostatic Intolerance
Terminated	`NCT00748228` - Dopamine in Orthostatic Tolerance	N/A
Active, not recruiting	`NCT05630040` - VNS for Long-COVID-19	N/A
Recruiting	`NCT04632134` - Long-term Effects of Transcutaneous Vagal Nerve Stimulation on Postural Orthostatic Tachycardia Syndrome (POTS)	N/A
Completed	`NCT00685919` - Peripheral Dopamine in Postural Tachycardia Syndrome	Phase 2/Phase 3
Completed	`NCT00061009` - Hypnosis in Autonomic Function	N/A
Recruiting	`NCT05618054` - Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Natural History With Its Numerous Co-morbidities?	N/A
Completed	`NCT01366963` - Cognitive Dysfunction in Postural Tachycardia Syndrome	N/A
Recruiting	`NCT05107635` - Inappropriate Sinus Tachycardia Registry
Terminated	`NCT02154009` - Clinical Autonomic Disorders: A Training Protocol
Completed	`NCT03602482` - Standing Cognition and Co-morbidities of POTS Evaluation	N/A
Completed	`NCT02167412` - EEG Characteristics in Youth POTS and/or Syncope

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.